| Name | Title | Contact Details |
|---|
IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.
Carterra, formerly Wasatch Microfluidics, develops high throughput surface plasmon resonance array-based platforms for biomolecular interaction analysis.
Molecular Express is a Rancho Dominguez, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orchestra BioMed is a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.
Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.